HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study.

AbstractOBJECTIVES:
We previously estimated the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies following the first pandemic wave at 2.23% in Québec, Canada. Following the much bigger second wave in fall 2020 and early 2021, we estimated the seroprevalence of anti-SARS-CoV-2 in Québec during the first months of 2021.
METHODS:
Blood samples from regular, asymptomatic (for ≥ 14 days) donors were collected between January 25, 2021 and March 11, 2021. Anti-SARS-CoV-2 seropositivity was assessed using an enzyme-linked immunosorbent assay that captures antibodies directed against the receptor binding domain of the SARS-CoV-2 spike (and hence cannot discriminate between infection- and vaccine-induced seropositivity). Seroprevalence estimates were adjusted for regional distribution, age, and sex.
RESULTS:
Samples from 7924 eligible donors were analyzed, including 620 (7.8%) vaccinated donors and 7046 (88.9%) unvaccinated donors (vaccination status unknown for 258 (3.3%) donors). Overall, median age was 51 years; 46.4% of donors were female. The adjusted seroprevalence was 10.5% (95% CI = 9.7-11.3) in the unvaccinated population and 14.7% (95% CI = 13.8-15.6) in the overall population. Seroprevalence gradually decreased with age and was higher among donors who self-identified as having a racial/ethnic background other than white, both in the overall and in the unvaccinated populations.
CONCLUSION:
The seroprevalence of SARS-CoV-2 antibodies significantly increased in Québec since spring 2020, with younger persons and ethnic minorities being disproportionately affected. When compared with the cumulative incidence rate reported by public health authorities (i.e., 3.3% as of March 11, 2021), these results suggest that a substantial proportion of infections remain undetected despite improvements in access to COVID-19 testing.
AuthorsAntoine Lewin, Gaston De Serres, Yves Grégoire, Josée Perreault, Mathieu Drouin, Marie-Josée Fournier, Tony Tremblay, Julie Beaudoin, Amélie Boivin, Guillaume Goyette, Andrés Finzi, Renée Bazin, Marc Germain, Gilles Delage, Christian Renaud
JournalCanadian journal of public health = Revue canadienne de sante publique (Can J Public Health) Vol. 113 Issue 3 Pg. 385-393 (06 2022) ISSN: 1920-7476 [Electronic] Switzerland
PMID35380364 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2022. The Author(s) under exclusive license to The Canadian Public Health Association.
Chemical References
  • Antibodies, Viral
Topics
  • Antibodies, Viral
  • Blood Donors
  • COVID-19 (epidemiology)
  • COVID-19 Testing
  • Cross-Sectional Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Quebec (epidemiology)
  • SARS-CoV-2
  • Seroepidemiologic Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: